The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F10%3A%230000116" target="_blank" >RIV/00209805:_____/10:#0000116 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/10:00051809

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers

Original language description

A protein named anterior gradient-2 (AGR2) was identified in breast cancer cell lines as a potentially novel oncogene overexpressed in estrogen receptor (ER) positive tumours. We show that AGR2 expression promotes cancer cell survival in clonogenic assays and increases cell proliferation and viability in a range of cancer cell lines. Chromatin immunoprecipitation and reporter assays indicate that AGR2 is transcriptionally activated by estrogen through ERa. However, we also found that AGR2 expression iselevated rather than inhibited in response to tamoxifen. Clinical analysis indicates that AGR2 expression is related to treatment failure in ERapositive breast cancers treated with tamoxifen. In contrast, AGR2 is one of the most highly suppressed genes in cancers of responding patients treated with the anti-hormonal drug letrozole. The AGR2 pathway represents a novel pro-oncogenic pathway for evaluation as anti-cancer drug developments, especially therapies that by-pass the agonist effec

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2010

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Oncogene

ISSN

0950-9232

e-ISSN

—

Volume of the periodical

29

Issue of the periodical within the volume

34

Country of publishing house

GB - UNITED KINGDOM

Number of pages

10

Pages from-to

—

UT code for WoS article

000281326400009

EID of the result in the Scopus database

—